The literature has underlined an association between HER2 activating mutations in colorectal cancer and resistance to therapy. While these mutations reduce the efficacy of EGFR antibody agents such as cetuximab the tumors remain responsive to dual HER2 targeted therapy with tyrosine kinase inhibitors like neratinib(1). Additionally, while we detect activating mutations in about 7% of […]
Featured Contributor
Adil Menon
Fourth-Year, Case Western Reserve School of Medicine
Before medical school, Adil completed his Master of Bioethics degree from Harvard Medical School. His written work may be found in Hektoen International, the HMS Bioethics Journal, the Pathologist, and JAMA Cardiology among other publications.
